Scotts Miracle-Gro has patented glufosinate-tolerant turfgrasses, including Kentucky bluegrass, and methods for their production and weed control. The patent includes a nucleic acid molecule encoding a phosphinothricin N-acetyltransferase enzyme. GlobalData’s report on Scotts Miracle-Gro gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Scotts Miracle-Gro, was a key innovation area identified from patents. Scotts Miracle-Gro's grant share as of February 2024 was 65%. Grant share is based on the ratio of number of grants to total number of patents.
Patent granted for glufosinate-tolerant turfgrasses
A recently granted patent (Publication Number: US11920141B2) discloses a nucleic acid molecule encoding a phosphinothricin N-acetyltransferase ("PAT") enzyme. The patent covers nucleic acid sequences with high sequence identity to specific sequences (SEQ ID NO: 1 and SEQ ID NO: 2) and their variants, enabling the production of recombinant plants or plant parts expressing the PAT enzyme. These genetically modified plants exhibit tolerance to glufosinate, a herbicide, and can include various grass species like Bahia grass, Bermuda grass, and Fescue grass, among others.
Furthermore, the patent extends to recombinant seeds, expression vectors, and turfgrass stands containing the genetically modified plants. It also encompasses a wide range of plant types beyond grasses, including grain crops, vegetables, fruits, ornamental flowers, and trees. The patent details the integration of the nucleic acid molecule into the plant genome, ensuring stable expression of the PAT enzyme. Additionally, it specifies plant parts that can be modified, such as cells, stems, leaves, and seeds, highlighting the versatility of the technology across different plant species, including Cannabis sativa varieties. The patent emphasizes the importance of sequence identity in the nucleic acid molecules for effective expression of the PAT enzyme, with variants having at least 97% to 99% sequence identity to the reference sequences (SEQ ID NO: 1 and SEQ ID NO: 2) being covered under the claims.
To know more about GlobalData’s detailed insights on Scotts Miracle-Gro, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

